Skip to Content
Stock Analyst Update

Maintaining Our FVE For BioNTech After Q3 Results

Details around its COVID-19 vaccine program were the highlight of Q3, but other drugs in the pipeline also demonstrated decent progress.

Mentioned:

Following no-moat BioNTech’s (BNTX) third-quarter results, we are maintaining our fair value estimate of $65 per share, which already factors in our 90% probability of approval for its COVID-19 vaccine, BNT162b2, partnered with Pfizer (ex-China) and Fosun Pharma (China). Details around its vaccine program were the highlight of the quarter, but other drugs in the pipeline also demonstrated decent progress.

As we discussed in our note from Nov. 9, the vaccine’s efficacy in the first interim analysis from its phase 3 COVID study was over 90%, which evaluated 94 disease cases (44,000 patients enrolled) based on a 2-dose schedule. We expect its final analysis at 164 confirmed cases by the end of this month, and we strongly believe that regulatory agencies are likely to authorize the vaccine for emergency use in late 2020. In preparation for its commercial launch with its partners, the company acquired a manufacturing facility in Germany to boost its production capacity, and Pfizer and BioNTech have a goal of producing 1.3 billion doses in 2021. Pfizer and BioNTech continue to add supply agreements with governments and have already secured contracts for 570 million doses in 2021, with options for 600 million more.

In oncology, the pandemic continued to adversely affect enrollment of studies and clinical site initiations overall. Trial plans for both BNT111 for advanced melanoma and BNT113 for HPV16+ head and neck cancer are currently under review by the U.S. Food and Drug Administration, and both phase 2 trials have been pushed back to start in the first half of 2021. In addition, the company provided positive early phase 1 data for BNT311, its next generation immunotherapy for solid tumors, partnered with Genmab. Recently published data showed that BNT311 was generally well tolerated, with no patients showing great transaminase elevations, and achieved disease control in about 66% of these heavily pretreated patients with solid tumors.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.